ThromboGenics NV is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company has a strong pipeline of drug candidates in cardiovascular diseases, visual disorders and cancer. The Company plans to show proof-of-concept for its products by taking them through to completion of Phase II clinical trials. To leverage its expertise, ThromboGenics forms development and marketing collaborations with experienced partners. The Company has its headquarters in Leuven, Belgium and subsidiaries in Ireland and the U.S.

Speaker Profile

Dr. De Haes

Dr. De Haes has over 20 years of experience in the global health care industry. He joined the Company from Roche, Switzerland, where he was Head of the Global Insulin Infusion business and member of the Executive Committee of Roche Diabetes Care. Before that, Dr. De Haes was President and CEO of Disetronic Medical Systems Inc, a leading company in insulin infusion therapy, Minneapolis, USA. At Sandoz Pharma in Basel, Switzerland, he led the development and commercialization of their first biotech product. Dr. De Haes holds a degree in Medicine from the University of Leuven and a corporate MBA from the University of St. Thomas, Minneapolis, USA.